-
Climate change main driver of European ocean warming: study
-
Trump, Carney talk as Canada seeks to hold off new US tariffs
-
Gauff finds a way into the Cincinnati fourth round
-
NASA images reveal crater left by SpaceX rocket's Moon crash
-
ZZ Top drummer Frank Beard dies at age 77
-
UN atomic watchdog says found tons of nuclear material at Syria site
-
Bayern's Musiala reveals 'neurological disorder' after on-field collapse
-
Ecuadoran diplomat enters race to be next UN chief
-
Angelique Kidjo immortalised on Hollywood Walk of Fame
-
US sanctions ICC chief Tomoko Akane of Japan
-
France to expel two Iranian diplomats: foreign minister
-
US moves to open vast tracts of pristine forests to logging
-
Spain's Granada closes iconic Alhambra as new quake hits
-
US sanctions International Criminal Court chief Tomoko Akane of Japan
-
Venus, Stephens, Monfils named among US Open wild cards
-
Meta hooked children and misled public: prosecutors
-
Rodri joins La Liga champions Barcelona from Manchester City
-
France's first women's rights minister Yvette Roudy dies, aged 97
-
Disney, ABC sue US regulator over threat to broadcast licenses
-
French producer Nicolas Altmayer, Dior PR chief Favier die in car crash
-
Trump, Carney hold talks as new US tariffs on Canada loom
-
Bezos consortium bought nearly 40 percent of Liverpool: report
-
Germany opens new drone research centre as security threats mount
-
Trump says no Iran talks planned, claims Hormuz 'new US territory'
-
How only a few tree species drive Amazon forest recovery
-
Canada seeks to avert new US tariffs as deadline looms
-
Ivonne A-Baki enters race to be next UN chief
-
US primaries test Democrat comeback hopes in Trump stronghold
-
Ukraine says Russian strike kills 10 in northeast region
-
Scientists discover how narwhals grow nature's only straight tusk
-
Meta in court over child social media addiction
-
DR Congo Ebola outbreak 'far from being under control': WHO chief
-
Vieira appointed Senegal head coach after World Cup disappointment
-
Firefighters in 'decisive' push to encircle Belgian wildfire
-
F1's Albon re-signs with Williams for 2027
-
Tribal Partners with ServiceNow to Empower Enterprise Teams to Build and Deploy Apps & Agents
-
Borderless.xyz Deepens Africa Coverage as CrissCross Goes Live on Its Network
-
Fusion Markets Extends Negative Balance Protection to Clients Globally
-
Pakistan court orders ex-PM Khan moved from jail to hospital
-
India close on victory in first Test against Sri Lanka
-
'Lonely place': Black UK academics slam racism after Arday's death
-
Three lightly injured as new quake hits Spain's Granada
-
UK PM says not embarrassed by hoax messages with fake Trump aide
-
Syria, US say Israel struck military air base in Idlib province
-
West Bank siege exposes Israel army inaction on settler violence
-
France probes Russian disinfo campaign against centrist candidates
-
Four-time champion Roglic to ride Vuelta after training crash
-
Stocks mostly drop as Mideast hopes dim, interest rates rise
-
Ukrainian convicted in Germany over Russian sabotage plot
-
Bayern's Musiala returns to training after on-field collapse
Moderna says US refusing to review mRNA-based flu shot
Vaccine manufacturer Moderna said Tuesday the US Food and Drug Administration was refusing to review an application for its first mRNA-based flu shot.
The move comes as the current iteration of the FDA has called for a reconsideration of approval procedures for certain vaccines, including for influenza -- proposed federal policy changes under President Donald Trump that have triggered widespread alarm among public health and medical professionals.
Moderna, a US company, said the agency's top vaccine regulator, Vinay Prasad, wrote in a letter that Moderna's clinical trial was not "adequate and well-controlled," and had not tested its experimental shot against the best product on the market.
In the large trial Moderna had compared its new vaccine with Fluarix, an approved flu shot from the company GSK.
Moderna said the rejection was "inconsistent with previous written communications" with the FDA branch that regulates biological products, including vaccines, known by the acronym CBER.
The decision "did not identify any safety or efficacy concerns with our product" and "does not further our shared goal of enhancing America's leadership in developing innovative medicines," Moderna CEO Stephane Bancel said in the statement.
"It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting."
Moderna said it had received a Refusal-to-File letter, which would indicate the application did not meet the requirements for substantive review. The company said it had requested a meeting to discuss the decision.
The letter did not identify any safety or efficacy concerns regarding the mRNA vaccine, said Moderna, which added the shot was accepted for review in the European Union, Canada and Australia.
During his first term Trump called mRNA technology a "modern-day miracle."
It was used during the Covid-19 pandemic to swiftly develop an immunization against the fast-spreading illness, and was credited with saving millions of lives.
Vaccines against Covid-19 are considered safe and effective by global health authorities, and protect against the most severe forms of the infection.
But in his second term, Trump has appointed Robert F. Kennedy Jr as his health chief, and the long-time vocal vaccine skeptic has spent the past year reshaping federal health agencies in his image.
That has meant spreading false information and sowing doubt about the safety and efficacy of vaccines widely known to be safe, and upending the pediatric immunization schedule.
Notably, Kennedy cut off federal research grants that funded mRNA development.
X.Habash--SF-PST